EUVIMEDEUVIMED entdecken
MetaanalyseSystematische Übersicht

Oral PCSK9 inhibitors as an emerging frontier in lipid management: A meta-analysis

Vinh Q T Ho, Nghi Bao Tran, Nhan Nguyen, David Downes, Giang Son Arrighini, Mrunalini Dandamudi, Rhanderson Cardoso, Juliana Giorgi

Journal of Clinical Lipidology · 2026-01 · 20 (1) · 31-43

DOI: 10.1016/j.jacl.2025.09.015 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Journal of Clinical Lipidology, 2026-01. Verfasst von Vinh Q T Ho und 7 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, University of Debrecen, Debrecen, Hungary (Drs Ho, Tran, and Nguyen). Hauptthemen laut MEDLINE: PCSK9 Inhibitors, Hypercholesterolemia. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 21 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) are effective lipid-lowering therapies that reduce cardiovascular risk in hypercholesterolemia. Recent advances include oral PCSK9i, which may offer advantages over injectables. PURPOSE: We aimed to assess the efficacy and safety of oral PCSK9i in reducing low-density lipoprotein cholesterol (LDL-C) levels, triglycerides, apolipoprotein B, and lipoprotein(a) compared with placebo on the background of standard medical therapy (SMT) in hypercholesterolemic populations. METHODS: This systematic review and meta-analysis included randomized controlled trials of oral PCSK9i vs placebo in patients with hypercholesterolemia at varying levels of atherosclerotic cardiovascular disease risk, and on stable lipid-lowering therapies. PubMed, Embase, and Cochrane were searched. Mean difference (MD) and odds ratio (OR) with 95% CI were pooled across trials for continuous and binary endpoints, respectively. RESULTS: We included 3 randomized controlled trials, with 1020 patients, of whom 804 (78.9%) received oral PCSK9i. The average patient age was 61.6 years, and 55.2% were male. Mean percent changes from baseline of LDL-C levels (MD = -47.83%; 95% CI: -54.91, -40.74; P < .00001), triglycerides (MD = -11.65%; 95% CI: -15.44, -7.87; P < .0001), apolipoprotein B (MD = -38.71%; 95% CI: -45.48, -31.93; P < .00001), and lipoprotein(a) (MD = -19.80; 95% CI: -25.60, -14; P < .0001) were significantly reduced in patients treated with oral PCSK9i compared with placebo on the background of SMT. Serious adverse events were not increased with oral PCSK9i (OR = 0.74; 95% CI: 0.34, 1.62; P = .45). CONCLUSION: Oral PCSK9i significantly reduced LDL-C, triglycerides, apolipoprotein B, and lipoprotein(a) without increasing serious adverse events. They show promise as effective, well-tolerated, and accessible lipid-lowering therapies for cardiovascular risk management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PCSK9 InhibitorsHypercholesterolemiaHumansAdministration, OralCholesterol, LDLRandomized Controlled Trials as TopicMaleFemaleMiddle AgedProprotein Convertase 9

Stichwörter der Autor:innen

Apolipoprotein BHypercholesterolemiaLDL cholesterolLipoprotein(a)Oral PCSK9 inhibitorsTriglycerides

Substanzen

PCSK9 InhibitorsPCSK9 protein, humanCholesterol, LDLProprotein Convertase 9

Autor:innen und Institutionen

  • Faculty of Medicine, University of Debrecen, Debrecen, Hungary (Drs Ho, Tran, and Nguyen).
  • Department of Rural Medicine, The University of New England, Armidale, NSW, Australia (Dr Downes).
  • Faculty of Medicine and Surgery, University of Bologna, Bologna, Italy (Dr Arrighini).
  • Department of Advanced Heart Failure and Transplant Cardiology, Montefiore medical center, Bronx, New York, USA (Dr Dandamudi).
  • Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA (Dr Cardoso).
  • Department of Cardiology, Hospital Sírio Libanês, São Paulo, Brazil (Dr Giorgi); Department of Cardiology, Hospital Albert Einstein, São Paulo, Brazil (Dr Giorgi). Electronic address: julianagiorgi@hotmail.com.

Zitieren

APA

Ho, V. Q. T., Tran, N. B., Nguyen, N., Downes, D., Arrighini, G. S., Dandamudi, M., Cardoso, R., & Giorgi, J. (2026). Oral PCSK9 inhibitors as an emerging frontier in lipid management: A meta-analysis. Journal of Clinical Lipidology, 20(1), 31-43. https://doi.org/10.1016/j.jacl.2025.09.015

Vancouver

Ho VQT, Tran NB, Nguyen N, Downes D, Arrighini GS, Dandamudi M, et al. Oral PCSK9 inhibitors as an emerging frontier in lipid management: A meta-analysis. Journal of Clinical Lipidology. 2026;20(1):31-43. doi:10.1016/j.jacl.2025.09.015

BibTeX
@article{Ho2026,
  author = {Ho, Vinh Q T and Tran, Nghi Bao and Nguyen, Nhan and Downes, David and Arrighini, Giang Son and Dandamudi, Mrunalini and Cardoso, Rhanderson and Giorgi, Juliana},
  title = {Oral PCSK9 inhibitors as an emerging frontier in lipid management: A meta-analysis},
  journal = {Journal of Clinical Lipidology},
  year = {2026},
  volume = {20},
  number = {1},
  pages = {31--43},
  doi = {10.1016/j.jacl.2025.09.015}
}
Kostenlos starten →